HALO stock

Halozyme Therapeutics Inc (HALO) support and resistance · P/E 15, rev $857.7M

Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.

This page maps Halozyme Therapeutics Inc (HALO) support and resistance from cached range and valuation — not a live tape and not a trade alert.

Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.

HALO currently screens at market cap $7.10B and trailing P/E 15.3. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.

A new HALO 8-K or 10-Q can move the levels that matter more than a drawing on a chart.

Not investment advice. Use the HALO quote page for the session range and the stock page for the full model.

Not investment advice.

Full HALO analysis